Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clinical Data submits antidepressant with companion Dx

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Clinical Data submits its NDA for vilazodone, a dual-acting selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist, for the treatment of major depressive disorder. In two eight-week Phase III trials, vilazodone was superior to placebo, with statistical significance for the primary and multiple secondary endpoints. Vilazodone would be set apart on the market by the availability of a companion diagnostic to identify patients most likely to benefit from treatment. Clinical Data is co-developing the test along with the drug. It estimates that peak sales could surpass $2 billion with the companion diagnostic (1"The Pink Sheet" DAILY, April 8, 2009)

You may also be interested in...

Clinical Data Psyched For Vilazodone NDA Filing In Second Half

Company anticipates data from a second Phase III trial evaluating the SSRI/5HT1A partial agonist for depression in the second quarter.

New Canadian Rule Allows Rolling Data Submissions For COVID-19 Drugs, Vaccines

The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.

‘No Turning Back’ On Regulatory Changes at UK MHRA

The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts